Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Neuberger Berman Group LLC

Neuberger Berman Group LLC lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 49.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,357 shares of the company's stock after selling 43,144 shares during the quarter. Neuberger Berman Group LLC's holdings in Moderna were worth $1,844,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new position in shares of Moderna in the fourth quarter worth $8,493,000. APG Asset Management N.V. boosted its stake in Moderna by 848.2% during the 4th quarter. APG Asset Management N.V. now owns 227,819 shares of the company's stock valued at $9,148,000 after purchasing an additional 203,792 shares in the last quarter. Advisory Services Network LLC increased its position in shares of Moderna by 543.1% during the 4th quarter. Advisory Services Network LLC now owns 19,603 shares of the company's stock valued at $815,000 after purchasing an additional 16,555 shares during the period. Capula Management Ltd bought a new stake in shares of Moderna in the 4th quarter worth $246,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Moderna by 225.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company's stock valued at $42,027,000 after buying an additional 700,458 shares during the period. Institutional investors own 75.33% of the company's stock.

Moderna Price Performance

Shares of NASDAQ:MRNA traded down $0.70 during trading hours on Thursday, hitting $24.49. 2,594,544 shares of the company's stock traded hands, compared to its average volume of 11,393,008. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47. The firm has a market capitalization of $9.47 billion, a P/E ratio of -2.64 and a beta of 2.23. The business has a fifty day moving average price of $31.10 and a 200-day moving average price of $40.37.

Wall Street Analyst Weigh In

MRNA has been the subject of several research analyst reports. Citigroup initiated coverage on shares of Moderna in a research report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target for the company. Royal Bank of Canada reissued a "sector perform" rating and set a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. Barclays downgraded shares of Moderna from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. UBS Group cut their price objective on Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. Finally, Evercore ISI set a $50.00 target price on Moderna in a research note on Friday, February 14th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.